Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.
Feliza Mirasol
Advertisement
Feliza Mirasol is the science editor for BioPharm International.
Articles by Feliza Mirasol
Process analytical testing for biopharmaceuticals requires enhanced methods due to complex bioprocesses.
The development of emerging therapies poses unique manufacturing and formulation challenges for drug developers as candidates like cell and gene therapies advance through the pipeline.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
WHO Finalizes United States’ Withdrawal from Organization: Report
3
Green Chemistry’s Role in Advancing US Chemical Innovation
4
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
5